157 related articles for article (PubMed ID: 7454084)
1. [Kinetics of anticoagulation in hemodialysis. Sequential study of single, intermittent and continuous heparinization].
Ghezzi PM; Di Siena F; Palanca R; Dutto A; Cento G
Minerva Med; 1980 Oct; 71(41):2987-91. PubMed ID: 7454084
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamics of unfractionated heparin during and after a hemodialysis session.
Brunet P; Simon N; Opris A; Faure V; Lorec-Penet AM; Portugal H; Dussol B; Berland Y
Am J Kidney Dis; 2008 May; 51(5):789-95. PubMed ID: 18436089
[TBL] [Abstract][Full Text] [Related]
3. [The impact of heparin bolus from dysfunctional lumen of dual lumen central venous catheter on activated partial thromboplastin time during hemodialysis: is additional heparinization necessary?].
Sefer S; Kes P; Raić B; Heinrich B; Degoricija V; Szavits-Nossan J
Acta Med Croatica; 2006 Jun; 60(3):281-5. PubMed ID: 16933844
[TBL] [Abstract][Full Text] [Related]
4. Tight heparin regimen for haemodialysis in children.
Ozen S; Saatçi U; Bakkaloğlu A; Uyumaz H; Kavukçu S
Int Urol Nephrol; 1993; 25(5):499-501. PubMed ID: 8270379
[TBL] [Abstract][Full Text] [Related]
5. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
6. Objective assessment of heparin requirements for hemodialysis in humans.
Ireland H; Lane DA; Curtis JR
J Lab Clin Med; 1984 Apr; 103(4):643-52. PubMed ID: 6230409
[TBL] [Abstract][Full Text] [Related]
7. [Use of activated coagulation time for evaluation of the degree of heparinization and calculation of heparin pharmacokinetic parameters during hemodialysis].
Khodas MIa; Piatnitskaia GKh; Lanskaia IM; Maksimenko VA; Savina ME
Urol Nefrol (Mosk); 1988; (3):42-8. PubMed ID: 3218006
[No Abstract] [Full Text] [Related]
8. [Anticoagulation in hemodialysis sessions with a low molecular weight heparin (CY 222, Choay). Dosage studies in chronic hemodialysis. Its use in patients at high risk of hemorrhage].
Dieval J; Morinière P; Roussel B; Bayrou B; Fournier A; Delobel J
J Mal Vasc; 1987; 12 Suppl B():114-8. PubMed ID: 2834482
[TBL] [Abstract][Full Text] [Related]
9. Heparin elimination and hemostasis in hemodialysis.
Wilhelmsson S; Lins LE
Clin Nephrol; 1984 Dec; 22(6):303-6. PubMed ID: 6525772
[TBL] [Abstract][Full Text] [Related]
10. A single dose of a low molecular weight heparin fragment for anticoagulation during hemodialysis.
Ljungberg B; Blombäck M; Johnsson H; Lins LE
Clin Nephrol; 1987 Jan; 27(1):31-5. PubMed ID: 3815906
[TBL] [Abstract][Full Text] [Related]
11. [Individual dosage schedule of heparin therapy in chronic hemodialysis by analytic studies of blood coagulation].
Gläser V; Anstadt M
Z Urol Nephrol; 1990 Mar; 83(3):133-40. PubMed ID: 2356667
[TBL] [Abstract][Full Text] [Related]
12. [Measurement of activated whole blood coagulation as a control parameter for heparin dosage in hemodialysis].
Kraatz G; Lopot F
Z Urol Nephrol; 1984 Aug; 77(8):465-71. PubMed ID: 6495895
[TBL] [Abstract][Full Text] [Related]
13. [The resistance of activated partial thromboplastin time to heparin infusion during hemodialysis].
Camici M; Sagripanti A; Barsotti G; Baicchi U; Evangelisti L; Morelli E; Giovannetti S
Minerva Med; 1995 Sep; 86(9):353-5. PubMed ID: 7501225
[TBL] [Abstract][Full Text] [Related]
14. Effect of a sliding scale protocol for heparin on the ability to maintain whole blood activated partial thromboplastin times within a desired range in hemodialysis patients.
Low CL; Bailie G; Morgan S; Eisele G
Clin Nephrol; 1996 Feb; 45(2):120-4. PubMed ID: 8846524
[TBL] [Abstract][Full Text] [Related]
15. [Hemodialysis without risk of hemorrhage. Introduction of an APTT bedside method for exact heparin monitoring--a review].
Vogel GE
Fortschr Med; 1977 Oct; 95(40):2437-44. PubMed ID: 924326
[TBL] [Abstract][Full Text] [Related]
16. [Renal replacement therapy by hemodialysis: an overview].
Jacobs C
Nephrol Ther; 2009 Jul; 5(4):306-12. PubMed ID: 19481513
[TBL] [Abstract][Full Text] [Related]
17. Whole-blood activated coagulation time for evaluation of heparin activity during hemodialysis: a comparison of administration by single-dose and by infusion.
Wilhelmsson S; Lins LE
Clin Nephrol; 1983 Feb; 19(2):82-6. PubMed ID: 6839556
[TBL] [Abstract][Full Text] [Related]
18. [Use of fragmin in program hemodialysis of patients with terminal chronic renal failure].
Kozlova TV; Shilo VIu; Denisov AIu
Klin Med (Mosk); 2005; 83(9):45-9. PubMed ID: 16279040
[TBL] [Abstract][Full Text] [Related]
19. Monitoring of heparins in haemodialysis using an anti-factor-Xa-specific whole-blood clotting assay.
Harenberg J; Haaf B; Dempfle CE; Stehle G; Heene DL
Nephrol Dial Transplant; 1995; 10(2):217-22. PubMed ID: 7753456
[TBL] [Abstract][Full Text] [Related]
20. The effects of three different heparin regimes on heparin concentrations in plasma and fibrin formation in dialyzers.
Gunnarsson B; Asaba H; Dawidson S; Wilhelmsson S; Bergström J
Clin Nephrol; 1981 Mar; 15(3):135-42. PubMed ID: 7273488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
